Researchers at the University of Geneva (UNIGE), Switzerland, and Geneva University Hospitals (HUG) have identified a DNA-binding factor called TOX that might play a role in triggering multiple...
Our news web pages include ground-breaking multiple sclerosis news and research from around the world.
These news stories are taken from external sources and as such, MS-UK does not verify, endorse or accept responsibility for their content.
Some of these pages have been written for medical professionals and this can be reflected in the complexity of language and content.
We’re here to support you, whether you are awaiting a diagnosis of multiple sclerosis or have been living with the condition for years.
Researchers at the University of Geneva (UNIGE), Switzerland, and Geneva University Hospitals (HUG) have identified a DNA-binding factor called TOX that might play a role in triggering multiple...
In December 2017 the National Institute of Health and Care Excellence (NICE) announced a...
The US Food and Drug Administration has approved Gilenya (fingolimod) to treat relapsing multiple sclerosis (MS) in children and adolescents age 10 years and older. This is the first FDA approval...
A study by the University of Birmingham has...
According to a French study, the approved cancer drug rituximab, which...
A new study, published in the May issue of Journal of Clinical Investigation, has...
A post-hoc analysis from the 2-year study CLARITY has...
A recent study has highlighted that...
According to a recent study, published at the 2018 AAN Annual Meeting in Los Angeles,...
US neurologists have reported the highest self-reported disease modifying therapy (DMT) switch rates in the US in the past three months. Active secondary progressive multiple sclerosis (SPMS) and...